<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of drug-resistant hypercholesterolemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of drug-resistant hypercholesterolemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of drug-resistant hypercholesterolemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Rosenson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sarah D de Ferranti, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Durrington, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mason W Freeman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypercholesterolemia, and in particular, an elevated level of serum (or plasma) low-density lipoprotein cholesterol (LDL-C), is associated with an increased risk of adverse cardiovascular events. Lipid lowering drug therapy, particularly with statins, is indicated to decrease the risk of cardiovascular events in most individuals with established atherosclerotic cardiovascular disease and in many who are at high risk. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease", section on 'Summary and recommendations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         Statins are the preferred therapy for most patients requiring treatment of dyslipidemia and in particular those with an elevated LDL-C. The goals of therapy are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         If after treatment with the maximal tolerated dose of statin the patient has not achieved the desired LDL-C reduction, a number of other agents are available with varying levels of evidence for clinical benefits. These agents include nicotinic acid (
         <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">
          niacin
         </a>
         ), bile acid sequestrants,
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         , and
         <a class="drug drug_general" data-topicid="127184" href="/z/d/drug information/127184.html" rel="external">
          bempedoic acid
         </a>
         and their use is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4562.html" rel="external">
          "Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors"
         </a>
         .)
        </p>
        <p>
         However, some patients, including young individuals with severe hypercholesterolemia, such as occurs in familial hypercholesterolemia, are unable to sufficiently lower their LDL-C to values with the use of these drugs. In addition some patients cannot receive high-intensity statin therapy due to statin related adverse effects. These individuals remain at high risk for cardiovascular events. For some of these, PCSK9 inhibition may be the next logical step in escalating their treatment and may be sufficiently effective, so that therapies already tried as adjuncts to statin therapy can be discontinued.
        </p>
        <p>
         This topic will discuss therapeutic options for these individuals, including PCSK9 inhibition, low-density lipoprotein (LDL) apheresis,
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         ,
         <a class="drug drug_general" data-topicid="127184" href="/z/d/drug information/127184.html" rel="external">
          bempedoic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="130778" href="/z/d/drug information/130778.html" rel="external">
          evinacumab
         </a>
         , as well as a number of procedures that are rarely performed such as partial ileal bypass surgery, liver transplantation, and portacaval shunting.
        </p>
        <p class="headingAnchor" id="H1557843">
         <span class="h1">
          LDL-C GOALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The desirable on-treatment level of low-density lipoprotein cholesterol (LDL-C) varies based on the patient’s risk of cardiovascular disease (CVD) events related to coexisting risk factors and the absence or presence of established CVD. In all patients, lifestyle modification and treatment with the maximal tolerated dose of statin (and possibly other medical therapy) should be tried. The goals of LDL-C lowering are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4567.html" rel="external">
          "Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17048.html" rel="external">
          "Dyslipidemia in children and adolescents: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1557919">
         <span class="h1">
          REFERRAL TO A SPECIALIST
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who have drug-resistant hypercholesterolemia, management decisions may be complicated. We recommend that they be referred to a physician who has substantial expertise in managing such individuals.
        </p>
        <p class="headingAnchor" id="H3978004270">
         <span class="h1">
          PHARMACOLOGIC THERAPIES
         </span>
        </p>
        <p class="headingAnchor" id="H82436065">
         <span class="h2">
          PCSK9 inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease produced predominantly in the liver that leads to the degradation of hepatocyte low-density lipoprotein (LDL) receptors and increased LDL-cholesterol (LDL-C) levels. Therapies that lower circulating PCSK9 levels significantly lower LDL-C levels. This category of therapy, including PCSK9 antibodies and siRNA (RNAi) inhibitors of PCSK9 synthesis such as
         <a class="drug drug_general" data-topicid="134700" href="/z/d/drug information/134700.html" rel="external">
          inclisiran
         </a>
         , is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/106888.html" rel="external">
          "PCSK9 inhibitors: Pharmacology, adverse effects, and use"
         </a>
         .)
        </p>
        <p>
         The role of PCSK9 inhibition in patients with established cardiovascular disease is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106888.html" rel="external">
          "PCSK9 inhibitors: Pharmacology, adverse effects, and use"
         </a>
         .)
        </p>
        <p>
         The potential role of PCSK9 inhibition in patients with homozygous familial hypercholesterolemia is discussed separately [
         <a href="#rid1">
          1
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/111815.html" rel="external">
          "Familial hypercholesterolemia in adults: Treatment"
         </a>
         ).
         <strong>
         </strong>
         Most studies report that the LDL-C reduction with PCSK9 inhibitors is 50 percent less in patients with homozygous familial hypercholesterolemia than heterozygous familial hypercholesterolemia [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4271016042">
         <span class="h2">
          ANGPTL3 Antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Angiopoietin-like 3 protein (ANGPTL3) inhibits endothelial lipase and lipoprotein lipase [
         <a href="#rid1">
          1
         </a>
         ]. The fully human monoclonal antibody
         <a class="drug drug_general" data-topicid="130778" href="/z/d/drug information/130778.html" rel="external">
          evinacumab
         </a>
         that binds circulating ANGPTL3 significantly lowers LDL-C by an LDL receptor independent pathway [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         Treatment with
         <a class="drug drug_general" data-topicid="130778" href="/z/d/drug information/130778.html" rel="external">
          evinacumab
         </a>
         has been shown to be effective in homozygous familial hypercholesterolemia regardless of the amount of residual LDL receptor activity. This agent is approved in the United States for treatment of hypercholesterolemia in patients with homozygous familial hypercholesterolemia. The medication is administered intravenously (15 mg/kg) every four weeks.
        </p>
        <p class="headingAnchor" id="H1978029418">
         <span class="h2">
          Bempedoic acid
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="127184" href="/z/d/drug information/127184.html" rel="external">
          Bempedoic acid
         </a>
         is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4562.html" rel="external">
          "Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors", section on 'Bempedoic acid'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2570836815">
         <span class="h2">
          Lomitapide
         </span>
         <span class="headingEndMark">
          —
         </span>
         In December of 2012, the United States Food and Drug Administration (FDA) approved the use of
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         for patients with
         <strong>
          homozygous
         </strong>
         familial hypercholesterolemia (FH), a rare inherited disorder that is estimated to occur in about one in a million individuals [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4567.html" rel="external">
          "Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Familial combined hyperlipidemia'
         </a>
         .)
        </p>
        <p>
         The United States product information for
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         carries a boxed warning regarding a serious risk of liver toxicity, as its use is associated with liver enzyme abnormalities. Lomitapide may be embryotoxic; women of child-bearing potential should have a negative pregnancy test before starting treatment and use effective contraception during treatment. The drug is also associated with a risk of severe diarrhea. This adverse event may be mitigated by adherence to a strict low fat diet.
        </p>
        <p>
         For patients with homozygous FH, we suggest adding
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         to treatment with a low-fat diet, lipid-lowering drugs including statins, and treatment with LDL apheresis or liver transplantation. For these patients who are not candidates for or refuse LDL-apheresis or liver transplantation, lomitapide should be considered as additional pharmacological therapy. (See
         <a class="local">
          'LDL apheresis'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          Lomitapide
         </a>
         is an inhibitor of microsomal triglyceride transfer protein, which transfers triglycerides onto apolipoprotein B as part of the assembly of very low-density lipoprotein within the liver [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">
          "Lipoprotein classification, metabolism, and role in atherosclerosis", section on 'Endogenous pathway of lipid metabolism'
         </a>
         .)
        </p>
        <p>
         The efficacy and safety of microsomal triglyceride transfer protein inhibition with the oral drug
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         have been evaluated in three small clinical studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of six patients with homozygous FH,
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         (at doses ranging between 0.03 and 1 mg/kg of body weight per day) decreased LDL-C by 51 percent and apolipoprotein B by 56 percent from baseline values [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent phase 2 study took into account the side effects of
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         noted above. In this trial, 84 patients with moderate hypercholesterolemia (LDL-C 130 to 250 mg/dL [3.4 to 6.5 mmol/L]) were randomly assigned to
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         , escalating doses of lomitapide (5, 7.5, and 10 mg per day), or ezetimibe plus escalating doses of lomitapide [
         <a href="#rid7">
          7
         </a>
         ]. After 12 weeks, LDL-C was lowered by 20, 30 (on 10 mg lomitapide), and 46 percent in the three groups, respectively. Lomitapide also reduced HDL-C by 6 percent and apolipoprotein B by 24 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an open-label, phase 3, nonrandomized, dose-escalating study, 29 patients with homozygous FH over the age of 18 were treated with
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         at a median dose of 40 mg daily [
         <a href="#rid8">
          8
         </a>
         ]. Most patients received high-dose statin, and 18 patients underwent regular apheresis. After 26 weeks of therapy, LDL-C was reduced by approximately 50 percent from baseline (from 336 to 166 mg/dL [8.7 mmol/L to 4.3 mmol/L]).
        </p>
        <p>
        </p>
        <p>
         In all three studies, the most common adverse events were gastrointestinal symptoms, increased liver aminotransferase levels (about 40 percent), and hepatic fat accumulation (about 8 percent). These side effects were dose-dependent. With regard to hepatic fat accumulation, one study showed stabilization at 30 percent after three years of therapy [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          Lomitapide
         </a>
         is started at 5 mg daily taken orally two or more hours after the evening meal. The dose may be increased after two weeks to 10 mg per day and, based upon tolerability and response, further gradual increases may be made at intervals of four weeks or more, up to the maximum daily dose of 60 mg [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          Lomitapide
         </a>
         is a substrate of cytochrome P450 3A4 (CYP3A4) hepatic metabolism and itself is an inhibitor CYP3A4 metabolism and P-glycoprotein efflux transporters; based upon its metabolic and hepatic effects, numerous significant drug interactions involving lomitapide are anticipated. As examples, the daily dose of lomitapide is limited to 30 mg when taken with weak CYP3A4 inhibitors (eg,
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">
          ranolazine
         </a>
         ), and use of lomitapide with moderate to strong inhibitors of CYP3A4 is contraindicated. A list of CYP3A4 inhibitors is provided separately in the table  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 1
         </a>
         ). Specific interactions may be determined by use of the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         .
        </p>
        <p>
         In the United States,
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         prescribing is restricted to physicians registered in a risk evaluation and mitigation strategy program whose requirements include: limiting use to patients with a diagnosis of
         <strong>
          homozygous
         </strong>
         FH, and excluding pregnancy and significant hepatic impairment (Child-Pugh B or C) prior to beginning treatment; the program also emphasizes close monitoring, including baseline and regular hepatic function tests (ie, at least monthly for first year) and educating patients about maintaining a diet supplying less than 20 percent of total calories as fat to reduce hepatic fat accumulation.
        </p>
        <p class="headingAnchor" id="H2483188093">
         <span class="h1">
          NONPHARMACOLOGIC THERAPIES
         </span>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          LDL apheresis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients at very high risk for serious cardiovascular events have not achieved their desired low-density lipoprotein cholesterol (LDL-C) reduction with standard lipid lowering therapy. LDL apheresis, which is approved by the United States Food and Drug Administration, has been recommended by some experts for these individuals. Patients who might be potential candidates include: those with coronary artery disease (CAD) and LDL-cholesterol levels greater than 200 mg/dL after standard therapy; and those without established CAD, but at high risk due to an LDL-cholesterol level greater than 300 mg/dL after dietary and pharmacologic intervention, particularly those who have additional risk such as first-degree relatives with premature CAD, high lipoprotein (a), or high-risk medical condition [
         <a href="#rid10">
          10
         </a>
         ]. Individuals with homozygous familial hypercholesterolemia (FH) usually are treated with LDL apheresis. We believe that clinical judgment plays an important role in the decision to use this burdensome therapy in these patients with or at high risk for cardiovascular disease. (See
         <a class="medical medical_review" href="/z/d/html/4566.html" rel="external">
          "Lipoprotein(a)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H325436636">
         <span class="h3">
          Procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         LDL apheresis refers to the extracorporeal removal of circulating apo B-containing lipoproteins, including LDL, lipoprotein (a), and very low-density lipoprotein (VLDL). There are multiple apheresis methods, including dextran sulphate cellulose adsorption, heparin-induced extracorporeal LDL cholesterol precipitation, immunoadsorption, and double filtration plasma pheresis of lipoproteins [
         <a href="#rid11">
          11
         </a>
         ]. The procedure is performed weekly or biweekly, determined in part by the rate at which LDL levels return to baseline after therapy. It is available at a limited number of centers and cost is in the range of 3000 to 4000 United States dollars per session.
        </p>
        <p class="headingAnchor" id="H325436643">
         <span class="h3">
          Efficacy and safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         LDL apheresis lowers LDL-C acutely by 50 to 76 percent [
         <a href="#rid12">
          12,13
         </a>
         ]. However, the time averaged exposure to LDL-C is more likely a better measure of efficacy than the single post-treatment value. This number is calculated using multiple between treatment values. While the optimal time-averaged LDL-C reduction is not known, a 30 percent reduction after six months and 38 percent after 18 months in the absence of statin therapy has been reported [
         <a href="#rid14">
          14
         </a>
         ]. Patients with higher baseline lipid levels appear to have a relatively greater response to this therapy [
         <a href="#rid15">
          15
         </a>
         ]. The range of time for return to baseline level of LDL-C varies between four days and three to four weeks.
        </p>
        <p>
         The most frequent side effects include hypotension, anemia, nausea, flushing, and headache. Venous access is necessary and many patients require construction of an arteriovenous fistula or placement of a central venous port, which increases the long-term complications [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8194.html" rel="external">
          "Central venous access in adults: General principles"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H325436658">
         <span class="h3">
          Outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         No study has demonstrated significantly improved survival with LDL apheresis [
         <a href="#rid16">
          16
         </a>
         ]. Some studies, which are limited by multiple potential sources of bias, the use of suboptimal doses of statins, or the enrollment of small numbers of patients, have suggested evidence of benefit for outcomes such as myocardial infarction. For example, in an observational study of 130 patients with heterozygous familial hypercholesterolemia (FH) who were treated with either LDL apheresis plus statin therapy (n = 43) or statin therapy (n = 87), there was a significantly lower rate of total coronary events (nonfatal myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, and death from coronary heart disease) in the LDL apheresis group (10 versus 36 percent, respectively) at six years [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         At least eight studies that evaluated angiographic parameters have evaluated the ability of LDL apheresis to reverse or delay the progression of atherosclerosis. Most of the patients in these studies had heterozygous FH; a few were homozygotes. Six of these studies were observational and in the aggregate did not show convincing evidence of regression [
         <a href="#rid18">
          18
         </a>
         ]. The two trials which randomly assigned patients to either LDL apheresis plus drug therapy or to drug therapy (
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         or simvastatin plus a bile acid sequestrant) alone did not show any significant difference in angiographic outcome:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Familial Hypercholesterolemia Regression Study randomly assigned 39 patients with heterozygous FH and coronary disease to biweekly LDL-apheresis plus
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         (40 mg/day) or to the same dose of simvastatin plus
         <a class="drug drug_general" data-topicid="9294" href="/z/d/drug information/9294.html" rel="external">
          colestipol
         </a>
         (20 g/day) [
         <a href="#rid19">
          19
         </a>
         ]. Repeat coronary angiography at approximately two years showed
         <strong>
          no difference
         </strong>
         in the mean change in luminal diameter but some secondary angiographic end points were biased in favor of drug therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The LDL-Apheresis Atherosclerosis Regression Study (LAARS) randomly assigned 42 patients with severe primary hypercholesterolemia (31 patients with heterozygous FH) and coronary atherosclerosis to biweekly LDL-apheresis plus
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         (40 mg/day) or to simvastatin alone [
         <a href="#rid20">
          20
         </a>
         ]. At two years, the mean reduction in LDL-C was 63 and 47 percent, respectively. There was no difference in the degree of coronary atherosclerosis between the two groups. Repeat angiography at about two years revealed no difference within or between the two groups in the degree of coronary atherosclerosis, although more minor lesions disappeared in the apheresis group. LAARS also noted an improvement in regional myocardial perfusion in patients treated with apheresis [
         <a href="#rid21">
          21
         </a>
         ] while another report showed improved endothelial function after a single apheresis [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Traditional coronary angiography is a relatively blunt outcome measure; several studies have demonstrated improvement in the following cardiovascular effects of LDL apheresis: endothelial function [
         <a href="#rid22">
          22
         </a>
         ], coronary vasodilation [
         <a href="#rid23">
          23
         </a>
         ], microvascular flow [
         <a href="#rid24">
          24
         </a>
         ], and myocardial perfusion [
         <a href="#rid15">
          15,25
         </a>
         ].
        </p>
        <p>
         The literature contains a number of case reports of children with homozygous FH undergoing LDL apheresis, many of whom had regression of xanthomata [
         <a href="#rid18">
          18
         </a>
         ]. The safety and efficacy of long-term LDL-apheresis was evaluated in a study of 11 children with severe genetic hypercholesterolemia (including children with homozygous FH) who were treated for 2 to 17 years [
         <a href="#rid26">
          26
         </a>
         ]. There were no cardiac deaths, non-fatal myocardial infarctions, or coronary revascularization procedures. Regression of established coronary artery lesions, as well as prevention of the development of new aortic and coronary lesions, was demonstrated.
        </p>
        <p class="headingAnchor" id="H174029240">
         <span class="h3">
          Clinical use
         </span>
         <span class="headingEndMark">
          —
         </span>
         As no study has demonstrated improved survival with LDL apheresis, and because there are known side effects and patient burden, related to venous access, frequent long visit, and high cost, experts vary in their recommendations for initiation of this therapy and insurers have widely varying thresholds for reimbursement.
        </p>
        <p>
         We believe LDL apheresis should be considered as an effective method of lowering LDL-C when the patient may experience substantial benefits. Benefit is likely to be greatest when an individual will be or has been exposed to very high LDL-C for many years; this can be thought of as the lifetime risk. We refer very few adult patients with
         <strong>
          heterozygous
         </strong>
         FH for the procedure (and no children). We think it is reasonable to consider LDL apheresis in
         <strong>
          homozygotes
         </strong>
         or those with analogous phenotypes such as compound heterozygotes
         <strong>
          if the patient has been treated with diet and pharmacotherapy and if LDL-C remains above the following cut-points
         </strong>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LDL-C ≥160 mg/dL in children (age less than 18 years) with established atherosclerotic CVD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LDL-C ≥250 mg/dL in children without established atherosclerotic CVD
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LDL-C ≥160 to 190 mg/dL in adults with established CVD
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LDL-C ≥190 mg/dL in adults without established CVD. A recommendation for the use of LDL-apheresis in these individuals should take into account not only the absolute LDL-C level, but also the presence or absence of other cardiovascular risk factors as well as the age of the patient. We consider recommending the procedure for younger individuals and other risk factors with an LDL-C of 190 mg/dL or higher, whereas our threshold for such a recommendation would be significantly higher for a patient without other risk factors or who was older than 50 years.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5093064">
         <span class="h3">
          Recommendations of others
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 2016 European Society of Cardiology/European Atherosclerosis Society Guideline for the management of dyslipidemias recommends LDL apheresis for those with homozygous familial hypercholesterolemia [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         The Third Report of the National (United States) Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report did not discuss LDL apheresis, in part because they were not intended to address patients with severe hypercholesterolemia associated with defined genetic disorders [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The 2011 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents makes the following statement: “Children with homozygous familial hypercholesterolemia (FH) and extremely elevated LDL-cholesterol levels (500 mg/dL) have undergone effective LDL lowering therapy with biweekly LDL apheresis under the care of lipid specialists in academic medical centers” [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         The National Lipid Associated Expert Panel on FH list the following as possible indications for LDL apheresis in patients who, after six months, do not have an adequate response to maximum tolerated drug therapy [
         <a href="#rid15">
          15,30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Functional homozygous FH patients with LDL-C ≥300 mg/dL (or non-high density lipoprotein cholesterol [HDL-C] 330 mg/dL).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Functional heterozygous FH patients with LDL-C ≥300 mg/dL (or non-HDL cholesterol 330 mg/dL and 0 to 1 risk factors).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Functional heterozygous FH patients with LDL-C ≥200 mg/dL (or non-HDL cholesterol 230 mg/dL) and high-risk characteristics such as ≥2 risk factors or high lipoprotein (a) ≥50 mg/dL using an isoform insensitive assay.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Functional heterozygous FH patients with LDL-C ≥160 mg/dL (or non-HDL cholesterol 190 mg/dL) and very high-risk characteristics such as established coronary heart disease, other cardiovascular disease, or diabetes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1662808827">
         <span class="h2">
          Liver transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Liver transplantation is a procedure that has been used in familial hypercholesterolemia homozygous patients to provide the functional hepatic low-density lipoprotein (LDL) receptors that these patients lack. Multiple case reports of children as young as five years of age have demonstrated that successful transplantation leads to normalization of LDL cholesterol (LDL-C) levels beginning as early as five days after surgery [
         <a href="#rid31">
          31-34
         </a>
         ]. For individuals with end-stage coronary artery disease, heart-liver transplant has been described [
         <a href="#rid35">
          35,36
         </a>
         ].
        </p>
        <p>
         We believe that liver transplantation is a reasonable treatment option for patients with homozygous familial hypercholesterolemia who do not have optimal LDL-C levels after treatment with maximal tolerated cholesterol lowering therapy and for whom receiving regular LDL-apheresis is not possible.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Partial ileal bypass surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of partial ileal bypass surgery was best assessed in the POSCH trial [
         <a href="#rid37">
          37-39
         </a>
         ]. The study population consisted of 838 patients, with an average age of 51 years, who had survived a first myocardial infarction. The mean follow-up period was 9.7 years. The following benefits were noted in those treated with surgery compared to the controls [
         <a href="#rid37">
          37
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 23 percent reduction in the serum total cholesterol concentration (181 versus 236 mg/dL [4.71 versus 6.14 mmol/L]).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 38 percent reduction in serum LDL-cholesterol.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A nonsignificant reduction in overall mortality and mortality due to coronary heart disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A significant 35 percent reduction in the combined end point of death due to coronary heart disease and confirmed nonfatal myocardial infarction.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A comparison of base-line coronary arteriograms with those obtained at 3, 5, 7, and 10 years consistently showed less disease progression in the surgery group.
        </p>
        <p>
        </p>
        <p>
         These benefits persisted for five years after the trial (total mean follow-up 14.7 years) with significant reductions in cardiovascular and overall mortality, confirmed nonfatal myocardial infarction, incidence of coronary artery revascularization and onset of clinical peripheral vascular disease [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The most common side effect of partial ileal bypass was diarrhea. Other problems included occasional kidney stones, gallstones, and intestinal obstruction [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         For these reasons, and because newer, less burdensome treatments are available, we do not recommend partial ileal bypass surgery for patients with drug-resistant hypercholesterolemia.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Portacaval shunt
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not recommend portacaval shunting for patients with drug-resistant hypercholesterolemia, except perhaps for those who cannot be transplanted or treated with LDL apheresis. Portacaval shunting has been evaluated in a limited number of cases [
         <a href="#rid40">
          40,41
         </a>
         ]. One case report described a six-year-old girl with homozygous familial hypercholesterolemia (FH) [
         <a href="#rid40">
          40
         </a>
         ]. Before surgery, the rate of synthesis of low-density lipoprotein (LDL) was fourfold higher than in normolipidemic subjects and the fractional catabolic rate for LDL was reduced to 33 percent of control values. Five months after shunt surgery, the rate of LDL synthesis had declined by 48 percent. This caused a 39 percent reduction in the plasma LDL-cholesterol concentration despite a modest decrease in LDL catabolism. The mechanism of benefit was not well understood. Potential complications include hepatic encephalopathy and pulmonary hypertension [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1142223">
         <span class="h1">
          POTENTIAL FUTURE APPROACHES
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are a few drugs under development that could be used in advance of the procedural interventions described in this topic to achieve desirable low-density lipoprotein cholesterol (LDL-C) levels.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Gene therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gene therapy, supplying the normal LDL receptor gene for the treatment of familial hypercholesterolemia (FH), has been tested in mice and human subjects [
         <a href="#rid42">
          42-44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H625825958">
         <span class="h2">
          CETP inhibition
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhibitors of cholesteryl ester transfer protein (CETP) significantly raise HDL-C levels. CETP inhibitors were tested and were found to be insufficiently effective to merit further development. (See
         <a class="medical medical_review" href="/z/d/html/4560.html" rel="external">
          "HDL cholesterol: Clinical aspects of abnormal values", section on 'CETP inhibition'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H678172342">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109532.html" rel="external">
          "Society guideline links: Lipid disorders in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/111343.html" rel="external">
          "Society guideline links: Primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115645.html" rel="external">
          "Society guideline links: Secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H325436680">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Some patients, including young individuals with severe hypercholesterolemia such as occurs in severe or compound heterozygous or homozygous familial hypercholesterolemia (FH), are unable to lower their low-density lipoprotein-cholesterol (LDL-C) to values that approach prespecified targets with diet and established lipid lowering therapy, including statins. These individuals remain at high risk for cardiovascular events.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pharmacotherapy
         </strong>
         – Options include PCSK9 inhibition,
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         ,
         <a class="drug drug_general" data-topicid="127184" href="/z/d/drug information/127184.html" rel="external">
          bempedoic acid
         </a>
         , and
         <a class="drug drug_general" data-topicid="130778" href="/z/d/drug information/130778.html" rel="external">
          evinacumab
         </a>
         . (See
         <a class="local">
          'Pharmacologic therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nonpharmacologic therapy
         </strong>
         – This includes LDL apheresis and procedures used less often, including partial ileal bypass surgery, liver transplantation, and portacaval shunting. (See
         <a class="local">
          'Nonpharmacologic therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults with heterozygous FH
         </strong>
         – For adults with heterozygous FH who, after six months of dietary and optimal drug therapy, including the use of PCSK9 inhibitors, have an LDL-C above 300 mg/dL (7.17 mmol/L), and have no established cardiovascular disease, or above 200 mg/dL (5.17 mmol/L) in the presence of established cardiovascular disease, we suggest low-density lipoprotein (LDL) apheresis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'LDL apheresis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We recognize that there are multiple factors that should be part of the decision to begin LDL apheresis. We believe it is reasonable to begin such therapy with LDL-C values as low as 160 mg/dL (4.10 mmol/L) in adults with heterozygous FH with evidence of advanced atherosclerotic cardiovascular disease. In addition, we believe it is reasonable to consider the use of LDL apheresis in selected patients with even lower LDL-C levels who have documented progression of their atherosclerotic disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with
         </strong>
         <strong>
          homozygous FH
         </strong>
         – For patients with
         <strong>
          homozygous
         </strong>
         FH who are on maximal medical therapy and have the following LDL-C values, we suggest either LDL-apheresis or liver transplantation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The decision between the two should be based on issues of availability, patient preference, and expertise in performing liver transplantation (including operative mortality) (see
         <a class="local">
          'LDL apheresis'
         </a>
         above and
         <a class="local">
          'Liver transplantation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         LDL-C ≥160 mg/dL in children (age less than 18 years) with established atherosclerotic CVD
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         LDL-C ≥250 mg/dL in children without established atherosclerotic CVD
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         LDL-C ≥160 to 190 mg/dL in adults with established CVD
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         LDL-C ≥190 mg/dL in adults without established CVD
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory hypercholesterolemia
         </strong>
         – FH patients without cardiovascular disease who do not achieve LDL-C &lt;200 mg/dL (5.17 mmol/L) or those with established disease who do not achieve an LDL-C &lt;160 mg/dL (4.10 mmol/L) after optimal drug therapy and LDL-apheresis, we suggest adding
         <a class="drug drug_general" data-topicid="87508" href="/z/d/drug information/87508.html" rel="external">
          lomitapide
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients who are not candidates for or refuse LDL-apheresis or liver transplantation, lomitapide should be considered as additional pharmacologic therapy.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rosenson RS. Existing and emerging therapies for the treatment of familial hypercholesterolemia. J Lipid Res 2021; 62:100060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blom DJ, Harada-Shiba M, Rubba P, et al. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial. J Am Coll Cardiol 2020; 76:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reeskamp LF, Millar JS, Wu L, et al. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol 2021; 41:1753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med 2020; 383:711.
          </a>
         </li>
         <li class="breakAll">
          http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381:40.
          </a>
         </li>
         <li class="breakAll">
          Lomitapide capsules. US Food &amp; Drug Administration (FDA) approved product information.  Revised August, 2014. US national Library of medicine. Available at: http://www.dailymed.nlm.nih.gov/ (Accessed on November 06, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon BR, Stein E, Jones P, Illingworth DR. Indications for low-density lipoprotein apheresis. Am J Cardiol 1994; 74:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson GR, Catapano A, Saheb S, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 2010; 21:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson GR, HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemphill LC. Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis. J Clin Lipidol 2010; 4:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfohl M, Naoumova RP, Klass C, et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res 1994; 35:1946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito MK, McGowan MP, Moriarty PM, National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Julius U. Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients. J Cardiovasc Dev Dis 2018; 5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998; 82:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson GR. LDL apheresis. Atherosclerosis 2003; 167:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson GR, Maher VM, Matthews S, et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995; 345:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroon AA, Aengevaeren WR, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93:1826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aengevaeren WR, Kroon AA, Stalenhoef AF, et al. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996; 28:1696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Igarashi K, Tsuji M, Nishimura M, Horimoto M. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. J Clin Apher 2004; 19:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato M, Amano I. Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis. Ther Apher Dial 2003; 7:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi K, Yamashita K, Tasaki H, et al. Evaluation of improved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL apheresis. Ther Apher Dial 2004; 8:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stefanutti C, Vivenzio A, Di Giacomo S, et al. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion 2009; 49:1461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Authors/Task Force Members:, Catapano AL, Graham I, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Atherosclerosis 2016; 253:281.
          </a>
         </li>
         <li class="breakAll">
          Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report National Cholesterol Education Program. NIH Publication No. 02-5215, National Heart, Lung, and Blood Institute, National Institutes of Health; 2002.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilheimer DW, Goldstein JL, Grundy SM, et al. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 311:1658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valdivielso P, Escolar JL, Cuervas-Mons V, et al. Lipids and lipoprotein changes after heart and liver transplantation in a patient with homozygous familial hypercholesterolemia. Ann Intern Med 1988; 108:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakaei F, Nikeghbalian S, Kazemi K, et al. Liver transplantation for homozygous familial hypercholesterolemia: two case reports. Transplant Proc 2009; 41:2939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maiorana A, Nobili V, Calandra S, et al. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transplant 2011; 15:E25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alkofer BJ, Chiche L, Khayat A, et al. Liver transplant combined with heart transplant in severe heterozygous hypercholesterolemia: report of the first case and review of the literature. Transplant Proc 2005; 37:2250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beal EW, Mumtaz K, Hayes D Jr, et al. Combined heart-liver transplantation: Indications, outcomes and current experience. Transplant Rev (Orlando) 2016; 30:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchwald H, Matts JP, Fitch LL, et al. Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA 1992; 268:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchwald H, Varco RL, Boen JR, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998; 158:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilheimer DW, Goldstein JL, Grundy SM, Brown MS. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest 1975; 56:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starzl TE, Putnam CW, Koep LJ. Portacaval shunt and hyperlipidemia. Arch Surg 1978; 113:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oka K, Pastore L, Kim IH, et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001; 103:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Craeyveld E, Jacobs F, Gordts SC, De Geest B. Gene therapy for familial hypercholesterolemia. Curr Pharm Des 2011; 17:2575.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4554 Version 58.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33716107" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Existing and emerging therapies for the treatment of familial hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32646561" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33691480" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32813947" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Evinacumab for Homozygous Familial Hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32813947" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Evinacumab for Homozygous Familial Hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17215532" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18506154" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23122768" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23122768" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7977068" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Indications for low-density lipoprotein apheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20935563" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18371971" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Recommendations for the use of LDL apheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21122676" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7868973" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21600528" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29747383" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9874053" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12618263" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : LDL apheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7898227" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8635262" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8962554" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8994420" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15095396" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12887725" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15663533" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Evaluation of improved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL apheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19389031" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27594540" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention&amp;Rehabilitation (EACPR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27594540" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention&amp;Rehabilitation (EACPR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22084329" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21600525" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6390206" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3277507" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Lipids and lipoprotein changes after heart and liver transplantation in a patient with homozygous familial hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19765481" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Liver transplantation for homozygous familial hypercholesterolemia: two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20846238" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Preemptive liver transplantation in a child with familial hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15964390" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Liver transplant combined with heart transplant in severe heterozygous hypercholesterolemia: report of the first case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27527917" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Combined heart-liver transplantation: Indications, outcomes and current experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2205799" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1512911" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9625405" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/172531" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/202223" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Portacaval shunt and hyperlipidemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11238273" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7584986" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21774774" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Gene therapy for familial hypercholesterolemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
